An attorney for Bristol Myers Squibb on Friday urged a New York federal judge to dismiss a $6.4 billion action against the pharmaceutical giant, claiming the plaintiff has no subject matter jurisdiction.

UMB Bank NA filed suit against Bristol Myers in 2021, alleging the company delayed approval of a cancer drug in order to dodge payments to shareholders of the former Celgene Corp. Bristol Myers acquired Celgene in 2019 for $80.3 billion.